LSH · Lakeside Holding Ltd
Substantial doubt about the company's ability to continue as a going concern.
“As of March 31, 2026, the Company had an accumulated deficit of approximately $8.1 million. For the nine months ended March 31, 2026, the Company incurred a net loss from continuing operations of approximately $3.5 million and the net cash used in operating activities from continuing operations was approximately $3.0 million. Losses have principally occurred as a result of the substantial resources required for general and administrative expenses associated with our operations. The continuation of the Company as a going concern is dependent upon the continued financial support from its external financing. The Company currently plans to fund its operations and support its ongoing acquisition projects mainly through cash flow from loans, issuance of notes and additional equity financing from outside investors, if necessary, to ensure sufficient working capital. However, there is no assurance that the Company will be successful in securing sufficient funds to sustain the operations. These factors, among others, raise the substantial doubt regarding the Company's ability to continue as a going concern.”View the 10-Q filed May 19, 2026
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 |
|---|---|---|---|
| $24.06M | $17.79M | $18.32M | |
| $18.04M | $14.91M | $14.6M | |
| $6.02M | $2.88M | $3.72M | |
| — | 16.18% | 20.29% | |
| $9.07M | $7.41M | $4.14M | |
| — | $53.43K | — | |
| $11.66M | $7.84M | $4.24M | |
| -$5.64M | -$4.96M | -$526.04K | |
| — | -27.88% | -2.87% | |
| $436.08K | $138.99K | $108.01K | |
| — | $28.12K | — | |
| -$109.32K | $14.91K | $230.43K | |
| -$5.75M | -$4.94M | -$295.61K | |
| — | $301.88K | -$67.34K | |
| — | -$5.25M | -$225.25K | |
| — | -29.49% | -1.23% | |
| — | -$3025 | — | |
| -$3.28M | -$5.24M | -$222.04K | |
| USD/shares | — | -$0.69 | -$0.04 |
| USD/shares | — | -$0.69 | -$0.04 |
| shares | — | 7.56M | 6M |
| shares | — | 7.56M | 6M |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2024–FY2025: $852.88K in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Asia | $14,819,977 | $13,081,165 | $5,531,468 |
| United States | $2,970,448 | $5,233,990 | $7,341,423 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Crossborder Airfreights Solutions | $9,246,780 | $10,441,320 | $4,799,206 |
| Cross Border Ocean Freights Solutions | $5,781,180 | $7,873,835 | $8,073,685 |
| Distribution of Pharmaceutical Products | $2,762,465 | — | — |